Cargando…
Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report
The combination of cetuximab (CTX) and chemotherapy, such as FOLFOX or FOLFIRI, is currently the standard treatment for metastatic colorectal cancer (mCRC). Zoledronic acid (ZOL) is used in patients with bone metastasis. We herein report our experience with the case of a 58-year-old male patient wit...
Autores principales: | Tokumaru, Yoshihisa, Matsuhashi, Nobuhisa, Takahashi, Takao, Tanahashi, Toshiyuki, Matsui, Satoshi, Imai, Hisashi, Tanaka, Yoshihiro, Yamaguchi, Kazuya, Yoshida, Kazuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482389/ https://www.ncbi.nlm.nih.gov/pubmed/31031973 http://dx.doi.org/10.3892/mco.2019.1836 |
Ejemplares similares
-
Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases
por: Suetsugu, Tomonari, et al.
Publicado: (2018) -
Safety and feasibility of laparoscopic intersphincteric resection for a lower rectal tumor
por: Matsuhashi, Nobuhisa, et al.
Publicado: (2017) -
Safety and feasibility of laparoscopic intersphincteric resection for a lower rectal tumor
por: Matsuhashi, Nobuhisa, et al.
Publicado: (2018) -
Rectal neuroendocrine tumor developing lateral lymph node metastasis after curative resection: a case report
por: Tokumaru, Yoshihisa, et al.
Publicado: (2020) -
A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer
por: Matsuhashi, Nobuhisa, et al.
Publicado: (2018)